investigate the other frequent mechanism through which CDKN2 can be inactivated, promoter hypermethylation, as no DNA was available in most cases. Earlier studies investigating hypermethylation of p15 also showed contradictory clinical outcomes. However, also in most of these studies, no difference between B-and T-ALL phenotype was made either.
. Survivin is a member of this family with a particular function that combines antiapoptotic potential with a role in cell cycle regulation. As a normal partner in the chromosome passenger protein complex, defective survivin function causes mitotic abnormalities with failure of cytokinesis that result in the appearance of multinucleated cells. 2, 3 Several lines of evidence support the antiapoptotic potential of survivin, although it does not seem to be essential for survival of some normal cell types. Moreover, loss of survivin was recently shown to elicit a p53-dependent checkpoint response (Yang et al, 4 and references therein). In addition to the first described isoform survivin-a, two other splice variants, survivin D-Ex3 and survivin-2B, have been identified that are structurally distinct and differentially regulated and localised in the cell. 5 Whereas survivin-a and survivin D-Ex3 have been shown to protect against different apoptotic stimuli, the role of survivin-2B is less clear, as it seems to have lost its antiapoptotic potential, and it has been suggested that it could function to titrate the two other isoforms. Recently, survivin-2B has been reported to be upregulated by p53 and act as a proapoptotic factor sensitising cells to apoptosis induced by doxorubicin. 6 Survivin expression is restricted in most adult tissues to the G2/M phase, after which it is degraded by the ubiquitinproteasome pathway. However, survivin is widely expressed in a variety of tumours and an adverse prognostic significance of its expression has been documented in some tumour types. A similar adverse prognostic significance has been reported for both AML and ALL, but contradictory data were subsequently reported for AML (Nakayama and Kamihira 7 and Carter et al, However, these studies have not considered the existence of differentially spliced survivin isoforms with different biologic properties. We sought to address these questions by developing real-time PCR primers specific for the different isoforms (Table 1 ) and determining the RNA levels of bone marrow aspirates of AML and ALL with a percentage of tumour cells X85%. The cases studied included five ALL samples of B cell (ALL-B), five ALL samples of T-cell origin (ALL-T) and 13 AML samples of different subtypes. Peripheral blood mononucleated cells and granulocytes were used as reproducible (intra-and interlaboratory) and lineage-related controls, for ALL and AML respectively. The efficiency of the PCR reactions was calculated for every plate and only plates with efficiencies between 85 and 100% were used for results.
We have detected expression of all the isoforms in the leukaemic and control samples. The expression levels of survivin isoforms obtained for the two control cell types (Figure 1) show comparable levels of survivin-a (othan 3-fold variation) and survivin-2B in both cell types, whereas the levels of survivin D-Ex3 are more than 22-fold higher in granulocytes relative to mononuclear cells. Therefore, normal mature blood cells lineages appear to require different patterns of relative abundance of survivin isoforms. For mononuclear cells, it is worth noting that the potentially proapoptotic isoform survivin-2B represents the most abundant RNA. For granulocytes, this isoform is still more abundant than survivin-a, but represents only about one-third of the mRNA of surviving D-Ex3. These results probably reflect the different biological roles of survivin isoforms and suggest that the expression of the antiapoptotic survivin D-Ex3 may contribute to survival of mature myeloid cells. This assumption is further reinforced by the comparison of the expression levels of survivin isoforms in acute leukaemias and their respective lineage-related mature controls. In fact, the significant difference of expression of survivin D-Ex3 in the two control cell types is reflected in the very different trends of relative variation of this isoform in the two types of leukaemia (Figure 2c and f) , even though the absolute levels of this isoform are generally but not drastically lower in AML than in ALL. All the ALL cases show increased RNA levels of survivin D-Ex3 compared to mononucleated cells, but for the AML cases, a decrease in RNA levels relative to granulocytes was observed. In contrast, both ALL and AML have upregulated survivin-a (Figure 2a and d) and heterogeneous variation of survivin-2B (Figure 2b and e) . Survivin-a is found to be upregulated in every leukaemia case studied, with particular significance in ALL, where the difference to control MNC levels is more than 10-fold for all except one case (and is also more than 10-fold higher when compared to the levels of granulocytes in 50% of the cases). Finally, survivin-2B shows much less variation from control levels than survivin-a and survivin D-Ex3, and it can be either moderately up-or downregulated since only one case of ALL and one case of AML show a more pronounced (around eight-to nine-fold) up-or downregulation, respectively.
Our results suggest that a more targeted approach of survivinbased therapies would probably be more efficient than strategies that do not distinguish the different isoforms in which collateral effects on mature myeloid cells by depleting them of survivin D-Ex3 can be predicted. In fact, our results indicate that although survivin-a and survivin-2B are relatively scarce in control peripheral blood cells, survivin D-Ex3 is widely expressed in granulocytes and might therefore have an important role in this type of cells. On the other hand, increased expression of survivin-a in both AML and ALL compared to their normal controls suggests that this could be a useful molecular target, particularly in ALL. We conclude that when considering survivin-based therapeutic strategies for acute leukaemias, targeting exon 3 should be preferred to minimise the risks of neutropenia and have maximal efficiency. Even though such a strategy will initially abrogate the proapoptotic survivin-2B, the above-mentioned p53 response will subsequently upregulate this isoform that may sensitise neoplastic cells to some chemotherapeutic drugs.
5 Table 1 Sequences of the primer pairs used in the real-time PCR reactions 
